3654 results for «382»
3654 results
New tricuspid valve devices
16 Nov 2025 – From PCR London Valves 2025
Examine new tricuspid valve devices and innovative procedural approaches, featuring cases of challenging anatomy with pacemaker lead repositioning, use of LuX-valve plus in massive regurgitation, position optimization in transjugular TTVR, and early clinical experiences from feasibility studies.
Curious TAVI scenarios: from valve-in-valve challenges to life-saving emergency TAVI
16 Nov 2025 – From PCR London Valves 2025
This session presents a series of challenging and unusual TAVI cases, addressing complex scenarios such as persistent gradients after valve-in-valve procedures, advanced sealing techniques for nodules, innovative snare methods, emergency TAVI following diagnostic catheterisation, combined aortic valve and aorta interventions, and the crucial role of echocardiography...
Emergency transcatheter valve interventions: alternative therapy or bridge to surgery?
16 Nov 2025 – From PCR London Valves 2025
This session offers a compelling case-based exploration of emergency transcatheter valve interventions, demonstrating their potential as life-saving alternatives or bridges to surgery in high-risk patients. Through detailed clinical scenarios including cardiogenic shock, acute papillary muscle rupture, and severe aortic regurgitation from infective endocarditis, participants gain practical...
Mastering simple and complex LAA closure: a step-by-step case-based approach
16 Nov 2025 – From PCR London Valves 2025
This case-based session offers a comprehensive approach to mastering left atrial appendage (LAA) closure, emphasizing the critical role of imaging from pre-procedural planning through execution. It covers patient selection, procedural strategies from experienced operators, device selection tailored to anatomy, and nuanced decision-making during challenging device releases...
Focus on the right ventricle: patient selection and clinical outcomes after tricuspid valve intervention
16 Nov 2025 – From PCR London Valves 2025
Focused on the often-overlooked right ventricle, this session elucidates methods for accurate assessment of right ventricular function prior to transcatheter tricuspid valve interventions. It explores the role of right heart catheterisation in patient selection and timing, and evaluates long-term remodeling patterns post-procedure, providing critical insights for...
Beyond TAVI
16 Nov 2025 – From PCR London Valves 2025
This session offers a glimpse into cutting-edge structural heart interventions beyond TAVI. It introduces novel devices in early development stages targeting aortic valve stenosis and leaflet modification, discusses strategies to facilitate or defer TAVI, and provides opportunities for engagement with early-stage start-up partners innovating in structural...
Hotline - TAVI - Part 1
16 Nov 2025 – From PCR London Valves 2025
This comprehensive session examines the latest evidence and clinical trial data on TAVI, including comparisons of balloon-expandable versus self-expanding valves in failed bioprostheses, techniques to reduce coronary obstruction risk, and real-world outcomes across diverse populations. Cost-effectiveness analyses and longitudinal studies further inform best practices for optimizing...
Featured research: latest advances in mitral TEER and valve repair technologies
16 Nov 2025 – From PCR London Valves 2025
This session presents featured research on mitral valve interventions, including two-year outcomes from the MitraClip G4 EXPAND study, comparative data of mitral TEER versus redo surgery in failed surgical repair, evidence from novel TEER programs in non-surgical centers, and safety and efficacy results of the NeoNova...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?
02 Sep 2024
Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.
Author
Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials
14 Nov 2021
Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.
Author
Evidence base: current data on TAVI durability and long-term outcomes
18 Jun 2026
This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.
Author
Author
ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines
29 Aug 2021
There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...
Author
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.
Author
